Palo Alto Investors LP lifted its position in Alexion Pharmaceuticals (NASDAQ:ALXN) by 1.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,135,845 shares of the biopharmaceutical company’s stock after buying an additional 18,203 shares during the quarter. Alexion Pharmaceuticals comprises 5.4% of Palo Alto Investors LP’s investment portfolio, making the stock its 7th largest holding. Palo Alto Investors LP’s holdings in Alexion Pharmaceuticals were worth $126,601,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Rhumbline Advisers grew its stake in shares of Alexion Pharmaceuticals by 3.9% in the 4th quarter. Rhumbline Advisers now owns 403,489 shares of the biopharmaceutical company’s stock valued at $48,253,000 after buying an additional 15,174 shares in the last quarter. Xact Kapitalforvaltning AB lifted its holdings in Alexion Pharmaceuticals by 9.0% in the 4th quarter. Xact Kapitalforvaltning AB now owns 45,832 shares of the biopharmaceutical company’s stock worth $5,481,000 after purchasing an additional 3,789 shares during the last quarter. Sphera Funds Management LTD. acquired a new stake in Alexion Pharmaceuticals in the 4th quarter worth approximately $14,351,000. Toronto Dominion Bank lifted its holdings in Alexion Pharmaceuticals by 13.6% in the 4th quarter. Toronto Dominion Bank now owns 96,222 shares of the biopharmaceutical company’s stock worth $11,507,000 after purchasing an additional 11,505 shares during the last quarter. Finally, Emory University lifted its holdings in Alexion Pharmaceuticals by 36.6% in the 4th quarter. Emory University now owns 16,773 shares of the biopharmaceutical company’s stock worth $2,006,000 after purchasing an additional 4,490 shares during the last quarter. 92.26% of the stock is owned by institutional investors and hedge funds.

In related news, EVP John J. Orloff sold 2,115 shares of the company’s stock in a transaction on Friday, June 8th. The stock was sold at an average price of $118.53, for a total value of $250,690.95. Following the completion of the transaction, the executive vice president now directly owns 31,790 shares in the company, valued at $3,768,068.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christopher J. Coughlin bought 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 30th. The stock was purchased at an average price of $120.79 per share, with a total value of $1,207,900.00. Following the completion of the purchase, the director now directly owns 26,333 shares of the company’s stock, valued at approximately $3,180,763.07. The disclosure for this purchase can be found here. Corporate insiders own 4.35% of the company’s stock.

ALXN has been the subject of several analyst reports. Citigroup boosted their target price on Alexion Pharmaceuticals from $170.00 to $173.00 and gave the stock a “buy” rating in a report on Monday, April 30th. BidaskClub upgraded Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, March 17th. Credit Suisse Group boosted their target price on Alexion Pharmaceuticals from $149.00 to $154.00 and gave the stock an “outperform” rating in a report on Tuesday, June 5th. ValuEngine lowered Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, March 1st. Finally, Raymond James restated a “buy” rating on shares of Alexion Pharmaceuticals in a report on Monday, April 23rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have issued a buy rating to the company’s stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $158.37.

Shares of NASDAQ ALXN opened at $118.83 on Thursday. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.35 and a quick ratio of 2.86. The firm has a market capitalization of $25.97 billion, a P/E ratio of 23.03, a PEG ratio of 1.05 and a beta of 1.11. Alexion Pharmaceuticals has a one year low of $102.10 and a one year high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, April 26th. The biopharmaceutical company reported $1.68 EPS for the quarter, beating analysts’ consensus estimates of $1.50 by $0.18. The business had revenue of $930.90 million during the quarter, compared to analyst estimates of $920.50 million. Alexion Pharmaceuticals had a return on equity of 13.70% and a net margin of 14.46%. Alexion Pharmaceuticals’s revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.38 earnings per share. equities analysts anticipate that Alexion Pharmaceuticals will post 6.28 EPS for the current year.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.